The URL can be used to link to this page

Home My WebLink About022323 Fred Hutch launches MET-X_ a 'transformative approach to metastatic disease'________________________________ ALERT: BE CAUTIOUS This email originated outside the organization. Do not open attachments or click on links if you are not expecting them. ________________________________ Metastatic cancer research center | Appelbaum award | Antibody research for transplants ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ View as Web page <https://secure.fredhutch.org/site/R?i=Nzz0fzpxMBamND6BTmCXqLlXHO7d4TczXcKC_fzZH4ISZ67Ze8ZU6w> <https://secure.fredhutch.org/site/R?i=PQgYF8y_BgNh7pJ3Ro5yN8itSFrWlodDMlMHww95Nf7qF7oeV0AcsA> <https://secure.fredhutch.org/images/content/pagebuilder/fhcc-eml-hdr-shadow.png> <https://secure.fredhutch.org/site/R?i=iLD_T2x6wTvBUA8XDG9v8DRyX81ZwHVp1dNM3HwvbbWs0dFuCMS1_w> February 23, 2023 ⋅ A monthly digest of the latest from Fred Hutch Center for Metastasis Research Excellence launches <https://secure.fredhutch.org/site/R?i=5Fgcd8aHDdy6LR21bR2yC4AaH9-awbO6rd3cZAaWAjb3nCU8mCI3_w> Metastatic cancer is deadly, although many stage 4 patients are able to prolong their lives with treatments. Metastatic cancer is also one of, if not the most, challenging areas of cancer biology, which is why there hasn’t been a ton of focused, funded metastatic research and few actual cures. Fred Hutchinson Cancer Center hopes to change that with the launch of the Center for Metastasis Research Excellence, or MET-X, a focused research program aiming to crack one of the toughest biological challenges in medicine. Led by translational researcher Cyrus Ghajar, PhD, MET-X will be an interdisciplinary and collaborative program focused solely on solid tumor metastasis: its detection and prevention, but also treatments and ultimately, cures for this advanced stage of cancer. Learn more about MET-X <https://secure.fredhutch.org/site/R?i=4SyiFvITjQyZotFYSNUuiV8Xrf5u8DDmIy-o7Wo59GlSG9SDKHXXEQ> . ________________________________ Lifetime Achievement award <https://secure.fredhutch.org/site/R?i=DKX4bQ-s6AFxt1GVYG3WKPDfYecdzme1nXiHdFgGcSguOejGEr8a8Q> Medical pioneer and longtime Fred Hutch leader Fred Appelbaum, MD, was honored <https://secure.fredhutch.org/site/R?i=bPF3REyUC1bTmaddOoYI5SqGkJjS1Q-kBPrIzBEUO6U7BP_dwY-9Iw> with a Lifetime Achievement Award from the American Society for Transplantation and Cellular Therapy at the organization’s annual meeting in Orlando, Florida earlier this month. ________________________________ The Latest How blood cancer research might help organ transplant patients <https://secure.fredhutch.org/site/R?i=e-h5ecPyaiaJSnj809mY_yOsXZ4Af7N-T8ZZQa-AyOZ7dCq9Wt4hsg> A research team led by Fred Hutch’s Joshua Hill, MD, are using their expertise in an entirely different field: to zero in on long-lived plasma cells that may be keeping donated organs out of reach for patients with kidney disease. A tiny battle within the sexes — at the genetic level <https://secure.fredhutch.org/site/R?i=WkfM9FizXxx_j2Kp7Dfb1YVDU8og_heuVQabbOM2dT_X9jbbrXOUFg> New work from scientists at Fred Hutch shows that certain genes in fruit flies used for DNA packaging have been conscripted into the tussle between X and Y chromosomes in sperm, shaping — and accelerating — their evolution. Blood and marrow transplant program recognized <https://secure.fredhutch.org/site/R?i=TKWm5h1ZeCLkKZZoKjKzLHfNQY9eWXIQyNu5EVe37n9PV2SLYyVyJQ> The Fred Hutch Blood and Marrow Transplant Program has been recognized in an annual data report from the Center for International Blood and Marrow Transplant Research (CIBMTR) as exceeding expectations for one-year survival rates in patients who have received allogenic transplants of blood-forming stem cells from healthy donors. Dr. Mark Groudine retires after four decades <https://secure.fredhutch.org/site/R?i=TfIQGyMPLOS6N3gZeI7GUhEhepp0j_XGlRv1Im8hmTnmlGYCUjtFyg> A leader at Fred Hutch and contributor to fundamental discoveries about the interplay between DNA’s packaging, 3D organization and gene expression, Groudine exemplified the organization’s breadth of scientific and clinical endeavors. Striving for the summit of Kilimanjaro <https://secure.fredhutch.org/site/R?i=b-gBY6uYECDz0uqagFSbAZdEwxciPEIrdY-2yNtbT9b_YfvXFE24lQ> How 20 biotech leaders — and two Fred Hutch faculty members — are tackling a mountain and cancer at the same time. Building out our clinical team <https://secure.fredhutch.org/site/R?i=gKPx7uRAMYh9YKQwrkO3nzoHXI5ZNDF074wEKVJFPWURWewvxx29Lg> We are hiring for clinical roles ahead of the opening of a new, leading-edge clinic on our Seattle campus this spring. Explore our opportunities <https://secure.fredhutch.org/site/R?i=b71SG1NTro4s1Zh vcEhnfMIIuSHykwBgFQ45WUmdZxQl0KTRvWF2rg> to help people navigate or prevent a life-changing disease, and work alongside experts in care and in science at the forefront of cancer research. ________________________________ Make the Next Breakthrough Possible! Accelerate discoveries with your gift today. <https://secure.fredhutch.org/site/R?i=oVxr420lhr4F_bsrsabadfwwMdeCGDh0djQWHtzgXzru18PYFbngHA> ________________________________ Share this newsletter with family or friends <https://secure.fredhutch.org/site/R?i=q8P0jAAIYokba5Hm5SheuQwAS1kyNkrj2GeiwuoOnkiGyFAHUo9bLg> <https://secure.fredhutch.org/site/R?i=zBVtknFdNcmALWVkhqrYzbOO10ee_zhbKrBTEMlC02Y124FAsQ2WSQ> 1100 Fairview Ave. N., Seattle, WA 98109 communications@fredhutch.org <mailto:communications@fredhutch.org> 206.667.5000 <https://secure.fredhutch.org/site/R?i=JUJr-EJ5-KA43FsMimSNHR-F8PKQleQbu5t2olFIKh1i6C7jPkcpOg> <https://secure.fredhutch.org/site/R?i=D_kWWM5qLxsOmLX9ZD8OYuM6JPzY5aFVAN327ruOh7qJ8Pay2Gw5Kg> <https://secure.fredhutch.org/site/R?i=oM7aMBZ60zQNBKEwZoXZ3BesFTu-s39vwIOhG0SAYaDw_9aS8wgcQQ> <https://secure.fredhutch.org/site/R?i=2DYSoj75weA57EHmKRAmxHk8gcEsBgYmEjtbPAPaik1eJcY-x1EDXA> ________________________________ Fred Hutchinson Cancer Center is a 501(c)(3) nonprofit organization. You can adjust your email preferences <http://engage.fredhutch.org/site/CO?i=kGPl30WkC62RBqV8FwJNJbo1ecdAG3Bx3xODjATqUtn9WSAWNonZ5yakykFZt1WO&cid=1021> at any time or contact us at optout@fredhutch.org <mailto:optout@fredhutch.org> to be removed from both mail and email lists. For information about our privacy practices, see our Privacy Policy <https://secure.fredhutch.org/site/R?i=AW3NieJb8iOfYCZ6H6QpISLKmT6Z-qF34fDR-zL5ZBcB2T0FTEBVAA> . © 2023 Fred Hutchinson Cancer Center. All rights reserved. <http://engage.fredhutch.org/site/PixelServer?j=J8ovHZlCIKqwajam2xowCLG1i_mViiOhZqQf2o3MuPxvkqQFRWOWrw> uster2.blackbaud.net (-); Thu, 23 Feb 2023 17:45:54 -0600 X-VirtualServer: ATX-MTA13-216-63, mta-LLLV.cluster2.blackbaud.net, 10.64.116.163 X-SMHeaderMap: mid="X-MailingID" X-Destination-ID: jeffbocc@co.jefferson.wa.us X-SMFBL: amVmZmJvY2NAY28uamVmZmVyc29uLndhLnVz X-VirtualServerGroup: ATX-MTA13-216-63 DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=mta-bbcspool.convio.net; s=selector1; t=1677195954; i=@mta-bbcspool.convio.net; h=FROM:Subject:TO:X-MailingID: Reply-To:Message-ID:List-Unsubscribe:x-campaignID:X-Gateway: Organization:Date:MIME-Version:Content-Type; bh=Lbq/BzkLw0XI5s8U HW8u8GgnI1AVA8S4MG1lvgymTwo=; b=YFnfTSzUAO3k9XcLxZBnkAJSSS9czitq bpekXmqMmZbbo3ViBXNdayp/PvgEO5c4qb1dtEVRpPJElF4IJMH3VnlP3yewgCKx GGJc/m5esnMGMec2zu3y6qcx5WXGSL/NuTDnG23IoOBDVgjp1Cr8ZUsZfyjQTuN+ IFBX02H6Ll0= FROM: "Fred Hutch News Service" <communications@fredhutch.org> Subject: Fred Hutch launches MET-X, a 'transformative approach to metastatic disease' TO: "Phil Johnson" <jeffbocc@co.jefferson.wa.us> X-MailingID: 00000::GP::d9f62a9a-5877-45fa-b5d4-e4f7d3236ed1::2455752c-7569-4bae-aaff-2c17abaf1003::1340655_51230_1679_E-mail-2::0 Return-Path: email_feedback_handler@bbcsreturn.convio.net Reply-To: Fred Hutch News Service <communications@fredhutch.org> Message-ID: <f4c1f0c9961445cb85fbe65e7aa0e7d6@fredhutch.org> List-Unsubscribe: <mailto:mail+_smverp_.00000.GP.d9f62a9a-5877-45fa-b5d4-e4f7d3236ed1.2455752c-7569-4bae-aaff-2c17abaf1003.1340655_51230_1679_E-mail-2.0._smverp_.jeffbocc=co.jefferson.wa.us@bbcsretur n.blackbaud.net> x-campaignID: Blackbaud_55795153133 X-Gateway: poolc2 Organization: Fred Hutchinson Cancer Center Date: Thu, 23 Feb 2023 18:45:55 -0500 MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="NextPart_05ec3bcf_0cc9_4c26_add8_b8e98c200b6c" X-BESS-ID: 1677195955-103605-5502-36776-1 X-BESS-VER: 2019.1_20230221.1854 X-BESS-Apparent-Source-IP: 216.235.195.63 X-BESS-Parts: H4sIAAAAAAACAzWMOwrDMBAF77K1C3k/fpKvElJoyQo3IUVUGIzvHhVR8xgG5j 0uirPTTn3sQp8v7Za1DDqGBJtt0Aprq4dLhOQi8WpZJFdWupfZH/3971kKdB64GRiuQI WKpAaxra2aUgW70f38ASf0TtqCAAAA X-BESS-Spam-Status: SCORE=0.00 using global scores of QUARANTINE_LEVEL=N/A KILL_LEVEL=5.0 tests=HTML_MESSAGE Received-SPF: pass (mx-inbound14-21.us-east-2a.ess.aws.cudaops.com: domain of email_feedback_handler@bbcsreturn.convio.net designates 216.235.195.63 as permitted sender) X-BESS-Spam-Report: Code version 3.2, rules version 3.2.2.246361 [from cloudscan9- 169.us-east-2a.ess.aws.cudaops.com] Rule breakdown below pts rule name description ---- ---------------------- -------------------------------- 0.00 HTML_MESSAGE BODY: HTML included in message X-BESS-Spam-Score: 0.00 X-BESS-BRTS-Status: 1 X-MS-Exchange-Organization-Network-Message-Id: 0d00ed12-8da0-4888-7d53-08db15f7ff2c X-MS-Exchange-Organization-AuthSource: mail2013ca1.internal.county.domain X-MS-Exchange-Organization-AuthAs: Anonymous